CovidChloroV1, Main, Exploration, bibRecord, 000062

Treatment Protocol for COVID-19 Based on T2R Phenotype.

Identifieur interne : 000062 ( Main/Exploration ); précédent : 000061; suivant : 000063

Treatment Protocol for COVID-19 Based on T2R Phenotype.

Auteurs : Mohamed A. Taha [États-Unis, Égypte] ; Christian A. Hall [États-Unis] ; Colin J. Shortess [États-Unis] ; Richard F. Rathbone [États-Unis] ; Henry P. Barham [États-Unis]

Source :

Viruses [ 1999-4915 ] ; 2021.

RBID : pubmed:33803811

Descripteurs français

KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Azithromycine (administration et posologie), Dexaméthasone (administration et posologie), Femelle (MeSH), Goût (MeSH), Humains (MeSH), Mâle (MeSH), Phénotype (MeSH), Protocoles cliniques (MeSH), Récepteurs couplés aux protéines G (génétique), Récepteurs couplés aux protéines G (métabolisme), Études prospectives (MeSH), Études rétrospectives (MeSH).
MESH :
- administration et posologie : Azithromycine, Dexaméthasone.
- génétique : Récepteurs couplés aux protéines G.
- métabolisme : Récepteurs couplés aux protéines G.
- Adulte, Adulte d'âge moyen, Femelle, Goût, Humains, Mâle, Phénotype, Protocoles cliniques, Études prospectives, Études rétrospectives.

English descriptors

KwdEn :
- Adult (MeSH), Azithromycin (administration & dosage), COVID-19 (drug therapy), COVID-19 (genetics), COVID-19 (metabolism), Clinical Protocols (MeSH), Dexamethasone (administration & dosage), Female (MeSH), Humans (MeSH), Male (MeSH), Middle Aged (MeSH), Phenotype (MeSH), Prospective Studies (MeSH), Receptors, G-Protein-Coupled (genetics), Receptors, G-Protein-Coupled (metabolism), Retrospective Studies (MeSH), SARS-CoV-2 (genetics), SARS-CoV-2 (physiology), Taste (MeSH).
MESH :
- chemical , administration & dosage : Azithromycin, Dexamethasone.
- drug therapy : COVID-19.
- genetics : COVID-19, Receptors, G-Protein-Coupled, SARS-CoV-2.
- metabolism : COVID-19, Receptors, G-Protein-Coupled.
- physiology : SARS-CoV-2.
- Adult, Clinical Protocols, Female, Humans, Male, Middle Aged, Phenotype, Prospective Studies, Retrospective Studies, Taste.

Abstract

COVID-19 has become a global pandemic of the highest priority. Multiple treatment protocols have been proposed worldwide with no definitive answer for acure. A prior retrospective study showed association between bitter taste receptor 38 (T2R38) phenotypes and the severity of COVID-19. Based on this, we proposed assessing the different T2R38 phenotypes response towards a targeted treatment protocol. Starting July 2020 till December 2020, we tested subjects for T2R38 phenotypic expression (supertasters, tasters, and nontasters). Subjects who were subsequently infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (diagnosed via PCR) were included. Based on their taster status, supertasters were given dexamethasone for 4 days; tasters were given azithromycin and dexamethasone +/- hydroxychloroquine for 7 days; and nontasters were given azithromycin and dexamethasone for 12 days. Subjects were followed prospectively and their outcomes were documented. Seven hundred forty-seven COVID-19 patients were included, with 184 (24.7%) supertasters, 371 (49.6%) tasters, and192 (25.7%) nontasters. The average duration of symptoms with the treatment protocol was 5 days for supertasters, 8.1 days for tasters, and 16.2 days for nontasters. Only three subjects (0.4%) required hospitalization (3/3 nontasters). Targeted treatment protocol showed significant correlation (p < 0.05) based on patients' T2R38 phenotypic expression. Assessing treatment protocols for COVID-19 patients according to their T2R38 phenotype could provide insight into the inconsistent results obtained from the different studies worldwide. Further study is warranted on the categorization of patients based on their T2R38 phenotype.

DOI: 10.3390/v13030503
PubMed: 33803811
PubMed Central: PMC8003114

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000152
to stream Main, to step Curation: 000152

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment Protocol for COVID-19 Based on T2R Phenotype.</title>
<author><name sortKey="Taha, Mohamed A" sort="Taha, Mohamed A" uniqKey="Taha M" first="Mohamed A" last="Taha">Mohamed A. Taha</name>
<affiliation wicri:level="2"><nlm:affiliation>Rhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Rhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809</wicri:regionArea>
<placeName><region type="state">Louisiane</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Otorhinolaryngology, Cairo University, Cairo 11451, Egypt.</nlm:affiliation>
<country xml:lang="fr">Égypte</country>
<wicri:regionArea>Department of Otorhinolaryngology, Cairo University, Cairo 11451</wicri:regionArea>
<wicri:noRegion>Cairo 11451</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hall, Christian A" sort="Hall, Christian A" uniqKey="Hall C" first="Christian A" last="Hall">Christian A. Hall</name>
<affiliation wicri:level="2"><nlm:affiliation>Rhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Rhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809</wicri:regionArea>
<placeName><region type="state">Louisiane</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Sinus and Nasal Specialists of Louisiana, Baton Rouge, LA 70809, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sinus and Nasal Specialists of Louisiana, Baton Rouge, LA 70809</wicri:regionArea>
<placeName><region type="state">Louisiane</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shortess, Colin J" sort="Shortess, Colin J" uniqKey="Shortess C" first="Colin J" last="Shortess">Colin J. Shortess</name>
<affiliation wicri:level="2"><nlm:affiliation>Rhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Rhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809</wicri:regionArea>
<placeName><region type="state">Louisiane</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rathbone, Richard F" sort="Rathbone, Richard F" uniqKey="Rathbone R" first="Richard F" last="Rathbone">Richard F. Rathbone</name>
<affiliation wicri:level="2"><nlm:affiliation>Rhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Rhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809</wicri:regionArea>
<placeName><region type="state">Louisiane</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Barham, Henry P" sort="Barham, Henry P" uniqKey="Barham H" first="Henry P" last="Barham">Henry P. Barham</name>
<affiliation wicri:level="2"><nlm:affiliation>Rhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Rhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809</wicri:regionArea>
<placeName><region type="state">Louisiane</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Sinus and Nasal Specialists of Louisiana, Baton Rouge, LA 70809, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sinus and Nasal Specialists of Louisiana, Baton Rouge, LA 70809</wicri:regionArea>
<placeName><region type="state">Louisiane</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2021">2021</date>
<idno type="RBID">pubmed:33803811</idno>
<idno type="pmid">33803811</idno>
<idno type="doi">10.3390/v13030503</idno>
<idno type="pmc">PMC8003114</idno>
<idno type="wicri:Area/Main/Corpus">000152</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000152</idno>
<idno type="wicri:Area/Main/Curation">000152</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000152</idno>
<idno type="wicri:Area/Main/Exploration">000152</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Treatment Protocol for COVID-19 Based on T2R Phenotype.</title>
<author><name sortKey="Taha, Mohamed A" sort="Taha, Mohamed A" uniqKey="Taha M" first="Mohamed A" last="Taha">Mohamed A. Taha</name>
<affiliation wicri:level="2"><nlm:affiliation>Rhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Rhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809</wicri:regionArea>
<placeName><region type="state">Louisiane</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Otorhinolaryngology, Cairo University, Cairo 11451, Egypt.</nlm:affiliation>
<country xml:lang="fr">Égypte</country>
<wicri:regionArea>Department of Otorhinolaryngology, Cairo University, Cairo 11451</wicri:regionArea>
<wicri:noRegion>Cairo 11451</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hall, Christian A" sort="Hall, Christian A" uniqKey="Hall C" first="Christian A" last="Hall">Christian A. Hall</name>
<affiliation wicri:level="2"><nlm:affiliation>Rhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Rhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809</wicri:regionArea>
<placeName><region type="state">Louisiane</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Sinus and Nasal Specialists of Louisiana, Baton Rouge, LA 70809, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sinus and Nasal Specialists of Louisiana, Baton Rouge, LA 70809</wicri:regionArea>
<placeName><region type="state">Louisiane</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shortess, Colin J" sort="Shortess, Colin J" uniqKey="Shortess C" first="Colin J" last="Shortess">Colin J. Shortess</name>
<affiliation wicri:level="2"><nlm:affiliation>Rhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Rhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809</wicri:regionArea>
<placeName><region type="state">Louisiane</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rathbone, Richard F" sort="Rathbone, Richard F" uniqKey="Rathbone R" first="Richard F" last="Rathbone">Richard F. Rathbone</name>
<affiliation wicri:level="2"><nlm:affiliation>Rhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Rhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809</wicri:regionArea>
<placeName><region type="state">Louisiane</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Barham, Henry P" sort="Barham, Henry P" uniqKey="Barham H" first="Henry P" last="Barham">Henry P. Barham</name>
<affiliation wicri:level="2"><nlm:affiliation>Rhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Rhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809</wicri:regionArea>
<placeName><region type="state">Louisiane</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Sinus and Nasal Specialists of Louisiana, Baton Rouge, LA 70809, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Sinus and Nasal Specialists of Louisiana, Baton Rouge, LA 70809</wicri:regionArea>
<placeName><region type="state">Louisiane</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Viruses</title>
<idno type="eISSN">1999-4915</idno>
<imprint><date when="2021" type="published">2021</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term>
<term>Azithromycin (administration & dosage)</term>
<term>COVID-19 (drug therapy)</term>
<term>COVID-19 (genetics)</term>
<term>COVID-19 (metabolism)</term>
<term>Clinical Protocols (MeSH)</term>
<term>Dexamethasone (administration & dosage)</term>
<term>Female (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Phenotype (MeSH)</term>
<term>Prospective Studies (MeSH)</term>
<term>Receptors, G-Protein-Coupled (genetics)</term>
<term>Receptors, G-Protein-Coupled (metabolism)</term>
<term>Retrospective Studies (MeSH)</term>
<term>SARS-CoV-2 (genetics)</term>
<term>SARS-CoV-2 (physiology)</term>
<term>Taste (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Azithromycine (administration et posologie)</term>
<term>Dexaméthasone (administration et posologie)</term>
<term>Femelle (MeSH)</term>
<term>Goût (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Mâle (MeSH)</term>
<term>Phénotype (MeSH)</term>
<term>Protocoles cliniques (MeSH)</term>
<term>Récepteurs couplés aux protéines G (génétique)</term>
<term>Récepteurs couplés aux protéines G (métabolisme)</term>
<term>Études prospectives (MeSH)</term>
<term>Études rétrospectives (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Azithromycin</term>
<term>Dexamethasone</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Azithromycine</term>
<term>Dexaméthasone</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>COVID-19</term>
<term>Receptors, G-Protein-Coupled</term>
<term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Récepteurs couplés aux protéines G</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>COVID-19</term>
<term>Receptors, G-Protein-Coupled</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Récepteurs couplés aux protéines G</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Clinical Protocols</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Phenotype</term>
<term>Prospective Studies</term>
<term>Retrospective Studies</term>
<term>Taste</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Femelle</term>
<term>Goût</term>
<term>Humains</term>
<term>Mâle</term>
<term>Phénotype</term>
<term>Protocoles cliniques</term>
<term>Études prospectives</term>
<term>Études rétrospectives</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">COVID-19 has become a global pandemic of the highest priority. Multiple treatment protocols have been proposed worldwide with no definitive answer for acure. A prior retrospective study showed association between bitter taste receptor 38 (T2R38) phenotypes and the severity of COVID-19. Based on this, we proposed assessing the different T2R38 phenotypes response towards a targeted treatment protocol. Starting July 2020 till December 2020, we tested subjects for T2R38 phenotypic expression (supertasters, tasters, and nontasters). Subjects who were subsequently infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (diagnosed via PCR) were included. Based on their taster status, supertasters were given dexamethasone for 4 days; tasters were given azithromycin and dexamethasone +/- hydroxychloroquine for 7 days; and nontasters were given azithromycin and dexamethasone for 12 days. Subjects were followed prospectively and their outcomes were documented. Seven hundred forty-seven COVID-19 patients were included, with 184 (24.7%) supertasters, 371 (49.6%) tasters, and192 (25.7%) nontasters. The average duration of symptoms with the treatment protocol was 5 days for supertasters, 8.1 days for tasters, and 16.2 days for nontasters. Only three subjects (0.4%) required hospitalization (3/3 nontasters). Targeted treatment protocol showed significant correlation (<i>p</i>
 < 0.05) based on patients' T2R38 phenotypic expression. Assessing treatment protocols for COVID-19 patients according to their T2R38 phenotype could provide insight into the inconsistent results obtained from the different studies worldwide. Further study is warranted on the categorization of patients based on their T2R38 phenotype.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33803811</PMID>
<DateCompleted><Year>2021</Year>
<Month>04</Month>
<Day>19</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>04</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>13</Volume>
<Issue>3</Issue>
<PubDate><Year>2021</Year>
<Month>03</Month>
<Day>18</Day>
</PubDate>
</JournalIssue>
<Title>Viruses</Title>
<ISOAbbreviation>Viruses</ISOAbbreviation>
</Journal>
<ArticleTitle>Treatment Protocol for COVID-19 Based on T2R Phenotype.</ArticleTitle>
<ELocationID EIdType="pii" ValidYN="Y">503</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.3390/v13030503</ELocationID>
<Abstract><AbstractText>COVID-19 has become a global pandemic of the highest priority. Multiple treatment protocols have been proposed worldwide with no definitive answer for acure. A prior retrospective study showed association between bitter taste receptor 38 (T2R38) phenotypes and the severity of COVID-19. Based on this, we proposed assessing the different T2R38 phenotypes response towards a targeted treatment protocol. Starting July 2020 till December 2020, we tested subjects for T2R38 phenotypic expression (supertasters, tasters, and nontasters). Subjects who were subsequently infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (diagnosed via PCR) were included. Based on their taster status, supertasters were given dexamethasone for 4 days; tasters were given azithromycin and dexamethasone +/- hydroxychloroquine for 7 days; and nontasters were given azithromycin and dexamethasone for 12 days. Subjects were followed prospectively and their outcomes were documented. Seven hundred forty-seven COVID-19 patients were included, with 184 (24.7%) supertasters, 371 (49.6%) tasters, and192 (25.7%) nontasters. The average duration of symptoms with the treatment protocol was 5 days for supertasters, 8.1 days for tasters, and 16.2 days for nontasters. Only three subjects (0.4%) required hospitalization (3/3 nontasters). Targeted treatment protocol showed significant correlation (<i>p</i>
 < 0.05) based on patients' T2R38 phenotypic expression. Assessing treatment protocols for COVID-19 patients according to their T2R38 phenotype could provide insight into the inconsistent results obtained from the different studies worldwide. Further study is warranted on the categorization of patients based on their T2R38 phenotype.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Taha</LastName>
<ForeName>Mohamed A</ForeName>
<Initials>MA</Initials>
<Identifier Source="ORCID">0000-0002-7745-4727</Identifier>
<AffiliationInfo><Affiliation>Rhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809, USA.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Otorhinolaryngology, Cairo University, Cairo 11451, Egypt.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hall</LastName>
<ForeName>Christian A</ForeName>
<Initials>CA</Initials>
<AffiliationInfo><Affiliation>Rhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809, USA.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Sinus and Nasal Specialists of Louisiana, Baton Rouge, LA 70809, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Shortess</LastName>
<ForeName>Colin J</ForeName>
<Initials>CJ</Initials>
<AffiliationInfo><Affiliation>Rhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rathbone</LastName>
<ForeName>Richard F</ForeName>
<Initials>RF</Initials>
<AffiliationInfo><Affiliation>Rhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Barham</LastName>
<ForeName>Henry P</ForeName>
<Initials>HP</Initials>
<AffiliationInfo><Affiliation>Rhinology and Skull Base Research Group, Baton Rouge General Medical Center, 8585 Picardy Ave., Suite 210, Baton Rouge, LA 70809, USA.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Sinus and Nasal Specialists of Louisiana, Baton Rouge, LA 70809, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2021</Year>
<Month>03</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Switzerland</Country>
<MedlineTA>Viruses</MedlineTA>
<NlmUniqueID>101509722</NlmUniqueID>
<ISSNLinking>1999-4915</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D043562">Receptors, G-Protein-Coupled</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C406821">taste receptors, type 2</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>7S5I7G3JQL</RegistryNumber>
<NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>83905-01-5</RegistryNumber>
<NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002985" MajorTopicYN="Y">Clinical Protocols</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003907" MajorTopicYN="N">Dexamethasone</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D043562" MajorTopicYN="N">Receptors, G-Protein-Coupled</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013649" MajorTopicYN="N">Taste</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword>
<Keyword MajorTopicYN="Y">T2R38</Keyword>
<Keyword MajorTopicYN="Y">bitter taste receptors</Keyword>
<Keyword MajorTopicYN="Y">solitary chemosensory cells</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year>
<Month>02</Month>
<Day>15</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2021</Year>
<Month>03</Month>
<Day>12</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2021</Year>
<Month>03</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2021</Year>
<Month>4</Month>
<Day>3</Day>
<Hour>1</Hour>
<Minute>15</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2021</Year>
<Month>4</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2021</Year>
<Month>4</Month>
<Day>20</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33803811</ArticleId>
<ArticleId IdType="pii">v13030503</ArticleId>
<ArticleId IdType="doi">10.3390/v13030503</ArticleId>
<ArticleId IdType="pmc">PMC8003114</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Biol Chem. 2017 May 19;292(20):8484-8497</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28373278</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2012 Nov;122(11):4145-59</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23041624</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Biol Evol. 2014 Feb;31(2):303-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24202612</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int Forum Allergy Rhinol. 2020 Nov;10(11):1255-1257</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32856411</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Mol Life Sci. 2015 Jan;72(2):217-36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25323130</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Agric Food Chem. 2007 Jul 25;55(15):6236-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17595105</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chem Senses. 2006 Jun;31(5):403-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16527870</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Microbiol. 2019 May 07;10:962</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31134013</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2017 Jan 11;7:40353</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28074885</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pulm Pharmacol Ther. 2010 Apr;23(2):97-106</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19895898</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Allergy Clin Immunol Pract. 2018 May - Jun;6(3):1078-1080</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29054707</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Physiol. 2017 Feb;149(2):181-197</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28053191</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>FASEB J. 2014 Mar;28(3):1181-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24285091</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Allergy Asthma Rep. 2010 Jan;10(1):67-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20425516</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rhinology. 2017 Mar 1;55(1):90-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28214914</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Respir Res. 2021 Jan 28;22(1):31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33509163</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Genet. 2010 Jul 01;11:60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20594349</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2020 Jan 29;368:m351</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31996342</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Clin Invest. 2020 Mar;50(3):e13209</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32003000</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Pharm Des. 2014;20(16):2684-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23886388</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>FASEB J. 2012 Dec;26(12):4827-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22964302</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2017 Apr 11;7:46166</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28397820</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int Forum Allergy Rhinol. 2018 May 9;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29742315</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2014 Mar;124(3):1393-405</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24531552</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Biol. 2005 Feb 22;15(4):322-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15723792</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Rhinol Allergy. 2017 Mar 1;31(2):85-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28452704</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int Forum Allergy Rhinol. 2016 Aug;6(8):783-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27309535</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Drug Discov. 2016 May;15(5):327-47</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26868298</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Immunol. 2007 Dec;19(6):711-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17928212</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2009 Aug 28;325(5944):1131-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19628819</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Otolaryngol Head Neck Surg. 2021 Jan 12;:194599820984788</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33433247</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):69-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31996494</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Physiol Lung Cell Mol Physiol. 2012 Dec 1;303(11):L956-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22962016</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Respir Cell Mol Biol. 2011 Aug;45(2):189-201</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21330463</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 22;395(10224):e35-e36</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32035018</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Laryngoscope. 2017 Jan;127(1):44-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27650657</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2014 Jul 22;9(7):e103107</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25050705</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am Rev Respir Dis. 1988 Mar;137(3):726-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3278666</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Physiol (Oxf). 2016 Apr;216(4):407-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26493384</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Nanotechnol. 2020 Aug;15(8):630-645</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32661375</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Respir Cell Mol Biol. 2019 May;60(5):541-553</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30383396</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2009 Dec 5;395(1):1-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19800091</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Chem Senses. 2010 Feb;35(2):157-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20022913</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Allergy Clin Immunol. 2018 Aug;142(2):460-469.e7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29778504</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2020 Jun;178:104787</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32251768</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2003 Feb 7;112(3):293-301</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12581520</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Cell Dev Biol. 2013 Mar;24(3):215-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22947915</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int Forum Allergy Rhinol. 2015 Feb;5(2):111-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25532854</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2014 Oct 23;9(10):e110373</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25340739</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Pharmacol. 2014 Oct 5;740:302-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25036266</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Physiol. 2007;69:401-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16945069</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2010 Nov;16(11):1299-304</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20972434</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Pharmacol. 2001 Oct 19;429(1-3):209-29</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11698042</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2008;3(12):e3974</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19092995</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>FASEB J. 2019 Jan;33(1):501-517</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30011231</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Immunol. 2001;2:11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11686851</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Hum Biol. 1989 Mar-Apr;16(2):131-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2729890</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Genet. 2005 Apr;67(4):275-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15733260</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Mol Sci. 2017 Feb 17;18(2):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28218655</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Physiol Lung Cell Mol Physiol. 2016 Feb 15;310(4):L365-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26684251</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Pulm Med. 2012 Jan;18(1):76-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22112996</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2019 Mar 19;116(12):5564-5569</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30819885</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2003 Nov;3(11):722-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14592603</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Égypte</li>
<li>États-Unis</li>
</country>
<region><li>Louisiane</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Louisiane"><name sortKey="Taha, Mohamed A" sort="Taha, Mohamed A" uniqKey="Taha M" first="Mohamed A" last="Taha">Mohamed A. Taha</name>
</region>
<name sortKey="Barham, Henry P" sort="Barham, Henry P" uniqKey="Barham H" first="Henry P" last="Barham">Henry P. Barham</name>
<name sortKey="Barham, Henry P" sort="Barham, Henry P" uniqKey="Barham H" first="Henry P" last="Barham">Henry P. Barham</name>
<name sortKey="Hall, Christian A" sort="Hall, Christian A" uniqKey="Hall C" first="Christian A" last="Hall">Christian A. Hall</name>
<name sortKey="Hall, Christian A" sort="Hall, Christian A" uniqKey="Hall C" first="Christian A" last="Hall">Christian A. Hall</name>
<name sortKey="Rathbone, Richard F" sort="Rathbone, Richard F" uniqKey="Rathbone R" first="Richard F" last="Rathbone">Richard F. Rathbone</name>
<name sortKey="Shortess, Colin J" sort="Shortess, Colin J" uniqKey="Shortess C" first="Colin J" last="Shortess">Colin J. Shortess</name>
</country>
<country name="Égypte"><noRegion><name sortKey="Taha, Mohamed A" sort="Taha, Mohamed A" uniqKey="Taha M" first="Mohamed A" last="Taha">Mohamed A. Taha</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000062 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000062 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:33803811
   |texte=   Treatment Protocol for COVID-19 Based on T2R Phenotype.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:33803811" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Treatment Protocol for COVID-19 Based on T2R Phenotype.

Treatment Protocol for COVID-19 Based on T2R Phenotype.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki